Search alternatives:
significant estimated » significant estimates (Expand Search), significantly mitigated (Expand Search), significantly overestimated (Expand Search)
estimated decrease » estimated release (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
significant estimated » significant estimates (Expand Search), significantly mitigated (Expand Search), significantly overestimated (Expand Search)
estimated decrease » estimated release (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
-
1621
ASMR of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021.
Published 2025Subjects: -
1622
-
1623
-
1624
-
1625
Incidence number, ASIR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1626
-
1627
DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1628
-
1629
-
1630
-
1631
-
1632
-
1633
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1634
-
1635
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1636
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1637
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1638
-
1639
-
1640
Forest plot displaying the risk of BDs occurrence by mining status, sex, type of malformation, system involved and the gestational age at birth.
Published 2024“…The variables on the right are associated with an increase in risk while those on the left are associated with a significant decrease in risk. …”